Matt Dellatore

“Maybe first, going back to InViewDX, could you provide a bit more color on just what drove the strong placements in the quarter? Specifically, you know, any notable trends you're seeing with regard to uptake or how clinics are utilizing the product across ear, blood, or FNA?”

“Maybe stepping back a bit, Chirag, you kicked off the call highlighting how AMUEL is in the most transformative period in the company's history. I think two big things that come to mind here is obviously the recent biosimilars integration and also the Pfizer-Glyph-1 partnership.”

“Maybe coming back to fast-acting meloxicam, just briefly, could you comment on whether priority review is still a possibility there? And then anything further you could share regarding the expected label?”

“Thanks for taking my question and congrats on the strong quarter and the deal announcement. Maybe first on capital allocation broadly, you know, if we if we think about free cash flow of $2.5 to $3 billion over the next several years.”

“I know this was a long time coming, so very exciting. Maybe two questions, if I may. First, just on to the commercial strategy for the new expanded portfolio. I see you have both, you know, the mega blockbusters like Doopey and Contruda and also many sub-5 billion assets in there.”